Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Rev Gastroenterol Peru ; 41(3): 164-168, 2021.
Artigo em Espanhol | MEDLINE | ID: mdl-34978553

RESUMO

OBJECTIVES: Knowing the current prevalence of hepatitis C virus infection has taken great importance nowdays due to the new advances in the treatment of hepatitis C virus infection in which the new direct-acting antivirals have demonstrated a high rate of sustained viral response. MATERIALS AND METHODS: This is a descriptive study based on the detection of anti VHC in the blood banks of â€Å“Ministerio de Salud del Perú†according to the information obtained from â€Å“Programa Nacional de Hemoterapia y Bancos de Sangre†(PRONAHEBAS). RESULTS: In our study, the prevalence of anti-hepatitis C antibodies in blood donors nationwide was 0.428% in 2016 and 0.301% in 2017. CONCLUSION: To know updated data about the prevalence of hepatitis C virus infection in our population. It is the first step to be able to treat the disease and drastically reduce the infection rate according to the WHO target for 2030.


Assuntos
Doadores de Sangue , Hepatite C Crônica , Antivirais , Humanos , Peru/epidemiologia , Prevalência
2.
Trials ; 22(1): 342, 2021 May 17.
Artigo em Inglês | MEDLINE | ID: mdl-34001174

RESUMO

OBJECTIVES: The general objective of this study is to test the hypothesis that administration of convalescent plasma from donors with previous diagnosis of severe COVID-19 pneumonia is safe and associated with a decrease in all-cause in-hospital mortality among hospitalized patients with COVID-19 at 30 days in comparison with standard treatment alone. The secondary objectives are as follows: (1) to assess the efficacy of convalescent plasma to reduce the length of hospitalization, (2) to assess the efficacy of convalescent plasma to reduce the length of ICU stay, and (3) to assess the efficacy of convalescent plasma on reducing the requirement of invasive mechanical ventilation or ICU stay. TRIAL DESIGN: PERUCONPLASMA is a IIb phase open label, randomized, superiority clinical trial with 1:1 allocation taking place in real life routine clinical practice at public hospitals in Lima, Peru. Participants will be randomized to receive convalescent plasma along with local standard treatment or local standard treatment alone. After allocation, all participants will be followed for a total of 30 days or until hospital discharge, whichever occurs first. PARTICIPANTS: The population for the study are patients with severe disease with a confirmed laboratory test for SARS-CoV-2 infection hospitalized in 3 tertiary-care hospitals in Lima, Peru. Subjects are eligible for the trial if they meet all of the following inclusion criteria: 1. Age 18 or older 2. Hospitalization due to COVID-19 with laboratory confirmation (either with serologic, molecular, or antigen test along with a compatible clinical presentation) 3. Severe or critical COVID-19 disease Severe illness was defined by 2 or more of the following: Respiratory rate of 22 or more Hypoxemia with oxygen saturation equal or less than 93% Abnormal blood gas analysis (PaO2 < 60 mmHg, PaCO2 > 50 mmHg, or Pa/FiO2 < 300) Critical disease was defined by either: Mechanical ventilation requirement less than 72 h. Shock. 4. Capacity to provide informed consent (patient or patient's direct relative) 5. Availability of convalescent plasma units compatible with ABO blood type of the subject. EXCLUSION CRITERIA: Subjects are not eligible for the trial if they meet any of the following criteria: 1. Contraindication for transfusion (e.g., prior anaphylaxis, congestive heart failure) 2. Hemodynamic instability (PA < 60 mmHg refractory to vasopressors) 3. Uncontrolled concomitant infections\ 4. Stupor or coma 5. Platelets < 50,000/µL or disseminated intravascular coagulation 6. Serum creatinine > 3.5 mg/dL or dialysis requirement 7. Total bilirubin > 6 mg/dL or jaundice of unknown etiology 8. Myocardial infarction or acute coronary syndrome 9. Active or recent (< 7 days) intracranial hemorrhage 10. Pregnancy Donors: The donors have to meet the following criteria: male between 30 and 60 years with a previous diagnosis of severe COVID-19-associated pneumonia within the last 3 months, with resolution of symptoms of at least 28 days. The rationale for including donors with severe disease is to maximize the probability of collecting convalescent plasma units with high titer of neutralizing antibodies, as the technology to measure this specific type of antibodies is not routinely available in Peru. Aliquots of plasma will be stored for future quantification of neutralizing antibodies. INTERVENTION AND COMPARATOR: Convalescent plasma from donors with previous severe COVID-19 is the investigational medical product. The experimental group will receive 1 to 2 units of 200 to 250 ml of convalescent plasma along with local standard treatment. The control group will receive local standard treatment alone. The participants randomized to plasma will have evaluations at 6 h and 24 h to specifically evaluate possible post transfusion events. All the participants will be evaluated at day 3, day 7, and day 30 after enrolment. MAIN OUTCOMES: Safety outcome: Incidence of serious adverse reactions related to convalescent plasma transfusion within 24 h after convalescent plasma administration. Efficacy outcomes: Mortality from any cause during hospitalization at 30 days post randomization. Length of hospitalization at 30 days post randomization or until hospital discharge. Duration of mechanical ventilation at 30 days post randomization or until hospital discharge. Length of hospitalization in an intensive care unit at 30 days post randomization or until hospital discharge. Exploratory: Oxygen requirement evolution at days 3 and 7. Score Sequential Organ Failure Assessment (SOFA) evolution at days 3 and 7. Dynamics of inflammatory marker (lymphocyte, C-reactive protein (CRP), D-dimer, lactate dehydrogenase (LDH)) evolution at days 3 and 7. Proportion of patients progressing to multi-organ failure at 30 days post randomization or until hospital discharge. Proportion of transfusion related adverse reactions at 30 days post randomization or until hospital discharge. RANDOMIZATION: Randomization will be carried out within the electronic case report form (eCRF) in 1:1 ratio (receive plasma/control) in a randomization process established by blocks of size 2, 4, and 6. Allocation to the treatment arm of an individual patient will not be available to the investigators before completion of the whole randomization process. Randomization blocks will be performed with "ralloc", Stata's randomization process v.16.0. Randomization through the eCRF will be available 24 h every day. BLINDING (MASKING): Both the participants and study staff will be aware of the allocated intervention. Blinded statistical analysis will be performed. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): The sample size was calculated using the Fleiss formula with continuity correction to detect a mortality reduction from 50 to 20% between the two treatment arms with a confidence level of 95% and a power of 80%. Based on this information, a total of 45 patients per arm would be needed. After adjustment for a drop-out rate of 10% after enrolment, a total of 50 patients per arm (100 patients in total) will be enrolled. TRIAL STATUS: Current protocol version: 5.0 dated January 04, 2021. Recruitment started on September 21, 2020, and is expected to finish by the end of March 2021. TRIAL REGISTRATION: Peruvian Register of Clinical Trials (REPEC) ID: PER-016-20, registered on June 27, 2020. Clinicaltrials.gov ID: NCT04497324 , registered on August 4, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.


Assuntos
COVID-19 , Adolescente , Transfusão de Componentes Sanguíneos , COVID-19/terapia , Humanos , Imunização Passiva , Masculino , Peru , Plasma , Ensaios Clínicos Controlados Aleatórios como Assunto , SARS-CoV-2 , Resultado do Tratamento , Soroterapia para COVID-19
3.
Rev. gastroenterol. Perú ; 41(3): 164-168, jul.-sep. 2021. tab
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1357341

RESUMO

RESUMEN Objetivos: Conocer la prevalencia actual de la infección por el virus de la hepatitis C a nivel nacional ha tomado una gran importancia en la actualidad debido a los nuevos avances en el tratamiento de la infección del virus de la hepatitis C en los que los nuevos antivirales de acción directa han demostrado una alta tasa de respuesta viral sostenida. Materiales y métodos: El presente es un estudio descriptivo basado en la detección del anti VHC en los bancos de sangre del Ministerio de Salud de acuerdo a la información obtenida del Programa Nacional de Hemoterapia y Bancos de Sangre. (PRONAHEBAS). Resultados: En nuestro estudio la prevalencia de anticuerpos contra el virus de hepatitis C en donantes de sangre a nivel nacional fue 0,428% en el año 2016 y 0,301% en el año 2017. Conclusiones: Conocer datos actualizados acerca de la prevalencia de la infección del virus hepatitis C en nuestra población constituye el primer paso para poder combatir la enfermedad y reducir drásticamente la tasa de infección de acuerdo a la meta de OMS, que consiste en erradicar las hepatitis virales para el año 2030.


ABSTRACT Objectives: Knowing the current prevalence of hepatitis C virus infection has taken great importance nowdays due to the new advances in the treatment of hepatitis C virus infection in which the new direct-acting antivirals have demonstrated a high rate of sustained viral response. Materials and methods: This is a descriptive study based on the detection of anti VHC in the blood banks of "Ministerio de Salud del Perú" according to the information obtained from "Programa Nacional de Hemoterapia y Bancos de Sangre" (PRONAHEBAS). Results: In our study, the prevalence of anti-hepatitis C antibodies in blood donors nationwide was 0.428% in 2016 and 0.301% in 2017. Conclusion: To know updated data about the prevalence of hepatitis C virus infection in our population. It is the first step to be able to treat the disease and drastically reduce the infection rate according to the WHO target for 2030.

4.
Rev Gastroenterol Peru ; 22(1): 84-7, 2002.
Artigo em Espanhol | MEDLINE | ID: mdl-11961573

RESUMO

Erythrocytosis is a well-known paraneoplastic syndrome of hepatocellular carcinoma (HCC), occurring in 1% of cases of this neoplasm. This report describes two HCC patients who manifested erythrocytosis in their clinical report. Similar features found in both patients were a large tumour burden, high concentration of hemoglobin and hematocrit, increased levels of serum alphafetoprotein (AFP) and positive HBsAg. Right lobectomy of the liver was performed. Histological findings of the specimen showed HCC of trabecular pattern. Hemoglobin and hematocrit returned to normal range after the operation.


Assuntos
Carcinoma Hepatocelular/complicações , Neoplasias Hepáticas/complicações , Policitemia/etiologia , Adulto , Humanos , Masculino
5.
Rev. gastroenterol. Perú ; 22(1): 84-87, 2002.
Artigo em Espanhol | LILACS, LIPECS | ID: lil-315491

RESUMO

La eritrocitosis es reconocida como uno de los síndromes paraneoplásicos asociados al carcinoma hepatocelular (HCC), ocurre entre el 1 por ciento y 3 por ciento de los casos de esta neoplasia. En este reporte describimos los casos clínicos de dos pacientes con HCC que presentaron eritrocitos. Ambos pacientes tuvieron un HCC gigante en el lóbulo derecho del hígado así como concentraciones elevadas de hemoglobina y hematocrito, niveles séricos incrementados de alfa feto proteína (AFP) y AgHBs positivo. Se les realizó hepatectomía derecha, en el estudio histológico se encontró carcinoma hepatocelular de tipo trabecular. Después de la cirugía la hemoglobina y el hematocrito retornaron a valores dentro del rango normal.


Assuntos
Humanos , Masculino , Adulto , Policitemia , Carcinoma Hepatocelular , Síndromes Paraneoplásicas
6.
Acta cancerol ; 35(1): 47-49, ene.-jun. 2007. ilus
Artigo em Espanhol | LILACS, LIPECS | ID: lil-673586

RESUMO

Se presenta la experiencia del uso del parche de sangre autólogo en pacientes con diagnóstico de fuga de aire persistente a través del drenaje torácico, producto de la complicación de fístula broncopleural. Estos pacientes luego de este tratamiento tuvieron resultados alentadores y pudieron salir de alta en buenas condiciones evitándose intervenciones quirúrgicas innecesarias para resolver esta complicación.


Is presented the experience of autologus blood patch in patients with persistent air leak related to broncho pleural fistulae. The follow up after the treatment of the patients showed good results and they discharged out from the hospital in good conditions and this treatment precluded innecesary surgery.


Assuntos
Humanos , Masculino , Feminino , Criança , Pessoa de Meia-Idade , Fístula Brônquica/complicações , Fístula Brônquica/terapia , Placa de Sangue Epidural , Placa de Sangue Epidural , Relatos de Casos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA